08.11.20
Rank: #10 (Last year: #10)
$521 Million ($1.52B total)
Prior Fiscal: $509 Million
Percentage Change: +2.5%
No. of Employees: 4,000 (total)
Global Headquarters: Princeton, N.J.
KEY EXECUTIVES:
Peter Arduini, President and CEO
Carrie Anderson, EVP and CFO
Glenn G. Coleman, EVP and COO
Robert T. Davis, Jr., EVP and President, OTT
Michael McBreen, EVP and President, Codman Specialty Surgical
New Jersey often gets a bad rap. From “What exit are you?” to references to the HBO hit, “The Sopranos,” it is commonly the butt of a joke. But many lifelong residents will tell you the ribbing doesn’t really bother them as anyone who downplays how fantastic N.J. can be has clearly only landed at Newark-Liberty International Airport on their way into New York City. From the beaches to the pine barrens to the world-class universities, it’s a wonderful place to live and work.
Apparently, Integra’s CEO agrees. “We looked hard and wide at other towns in New Jersey and other states before choosing this location,” Peter Arduini, the firm’s president and CEO stated at a ribbon-cutting ceremony in December 2019. “For a lot of good reasons, we just kept coming back to this area.”
The new Princeton headquarters, formerly occupied by pharmaceutical company Novo Nordisk, houses approximately 600 of the organization’s employees within the five-story structure. Meanwhile, it’s previous executive center is being refurbished to become a world-class technology center, where the company’s R&D team will work. The former headquarters location will also offer sales training and a site for professional surgeon training within a cadaver lab.
The announcement capped off a year that saw Integra Lifesciences enjoy modest gains over the prior fiscal, with a 3.1 percent increase overall in revenue gains. That translated to a $45 million rise to finish at $1.52 billion total revenue. Within its primary business segment—Codman Specialty Surgical, which accounts for an almost 2:1 ratio in revenue generation compared to the Orthopedics and Tissue Technologies (OTT) division—finished up 3.3 percent to tally $996 million.
The OTT revenues saw similar gains, posting 2.5 percent growth over 2018 to finish at $521 million. Sales of Wound Reconstruction and Care products were attributed as responsible for the increases, while the Extremity Orthopedics unit was flat year over year.
Citing the company’s doubling in size in recent years, primarily due to the 2017 Codman acquisition, Integra Lifesciences announced it was making a pair of moves with regard to its leadership. To oversee the company’s operations and a percentage of its labor force, Glenn Coleman was named chief operating officer (COO). Integra’s former financial chief is the company’s first COO as the position was newly created for his changing responsibilities.
“Looking at the opportunities ahead, the creation of the COO role will provide the oversight we need to accelerate our future growth. The move will also allow me to focus greater attention on our long-term strategic direction and spend more time with our customers,” explained Arduini.
Carrie Anderson was hired to replace Coleman as CFO, having served as chief accounting officer and corporate controller at Dover Corp.
The revised leadership team at Integra oversaw the launch of two noteworthy orthopedic solutions in 2019. First was the Titan Reverse Shoulder System-S (RSS-S), which included a new glenoid baseplate design. The novel design was accomplished using advanced imaging analysis to improve fit and stability for patients of varying anatomy. The new RSS-S baseplate was designed to achieve immediate fixation with an independent central screw, and the porous-coated central post allows the patient’s bone to grow onto the implant to further maximize the potential for long-term fixation.
“We designed the Titan Reverse Shoulder System-S to leverage the latest data on glenoid morphology in various patient populations, while streamlining the instrumentation to improve the flow of each case,” said Dr. Matthew Ramsey of the Rothman Institute and one of the thought leaders Integra worked with on the design of the system. “The new system builds upon the established legacy of our diaphyseal-fit humeral stems, which allow me to treat my patients without cement in primary and revision surgeries.”
About a month later, Integra announced the launch of the Panta 2 TTC Arthrodesis Nail System for tibio-talo-calcaneal (TTC) fusion of the ankle. TTC fusion is a reconstructive ankle surgery for severe arthritis and complex deformities in which bone-to-bone contact through compression is paramount for long-term success. Panta 2’s new carbon fiber targeting and compression device offers surgeons an unobstructed view intraoperatively of the system’s nail for improved visibility for positioning and identification that bone-to-bone contact has been achieved.
Looking to the potential for future product innovation, Integra also announced it was teaming with a group of orthopedists, Consortium of Focused Orthopedists LLC (CFO), to develop a short stem and stemless shoulder system. According to Integra, the design of the bone-sparing shoulder system will be competitively differentiated, with design features that address limitations of systems currently on the market.
“We designed this system to allow for patients to be anatomically suited to experience the bone-sparing benefits of a short stem,” said Dr. Armodios Hatzidakis, an orthopedic surgeon at Western Orthopaedics, and one of the design surgeons with CFO. “Integra is a proven leader in medical devices with a successful track record of commercializing innovative products that improve patients’ lives. They are a logical choice to partner with to bring this product to market.”
$521 Million ($1.52B total)
Prior Fiscal: $509 Million
Percentage Change: +2.5%
No. of Employees: 4,000 (total)
Global Headquarters: Princeton, N.J.
KEY EXECUTIVES:
Peter Arduini, President and CEO
Carrie Anderson, EVP and CFO
Glenn G. Coleman, EVP and COO
Robert T. Davis, Jr., EVP and President, OTT
Michael McBreen, EVP and President, Codman Specialty Surgical
New Jersey often gets a bad rap. From “What exit are you?” to references to the HBO hit, “The Sopranos,” it is commonly the butt of a joke. But many lifelong residents will tell you the ribbing doesn’t really bother them as anyone who downplays how fantastic N.J. can be has clearly only landed at Newark-Liberty International Airport on their way into New York City. From the beaches to the pine barrens to the world-class universities, it’s a wonderful place to live and work.
Apparently, Integra’s CEO agrees. “We looked hard and wide at other towns in New Jersey and other states before choosing this location,” Peter Arduini, the firm’s president and CEO stated at a ribbon-cutting ceremony in December 2019. “For a lot of good reasons, we just kept coming back to this area.”
The new Princeton headquarters, formerly occupied by pharmaceutical company Novo Nordisk, houses approximately 600 of the organization’s employees within the five-story structure. Meanwhile, it’s previous executive center is being refurbished to become a world-class technology center, where the company’s R&D team will work. The former headquarters location will also offer sales training and a site for professional surgeon training within a cadaver lab.
The announcement capped off a year that saw Integra Lifesciences enjoy modest gains over the prior fiscal, with a 3.1 percent increase overall in revenue gains. That translated to a $45 million rise to finish at $1.52 billion total revenue. Within its primary business segment—Codman Specialty Surgical, which accounts for an almost 2:1 ratio in revenue generation compared to the Orthopedics and Tissue Technologies (OTT) division—finished up 3.3 percent to tally $996 million.
The OTT revenues saw similar gains, posting 2.5 percent growth over 2018 to finish at $521 million. Sales of Wound Reconstruction and Care products were attributed as responsible for the increases, while the Extremity Orthopedics unit was flat year over year.
Citing the company’s doubling in size in recent years, primarily due to the 2017 Codman acquisition, Integra Lifesciences announced it was making a pair of moves with regard to its leadership. To oversee the company’s operations and a percentage of its labor force, Glenn Coleman was named chief operating officer (COO). Integra’s former financial chief is the company’s first COO as the position was newly created for his changing responsibilities.
“Looking at the opportunities ahead, the creation of the COO role will provide the oversight we need to accelerate our future growth. The move will also allow me to focus greater attention on our long-term strategic direction and spend more time with our customers,” explained Arduini.
Carrie Anderson was hired to replace Coleman as CFO, having served as chief accounting officer and corporate controller at Dover Corp.
The revised leadership team at Integra oversaw the launch of two noteworthy orthopedic solutions in 2019. First was the Titan Reverse Shoulder System-S (RSS-S), which included a new glenoid baseplate design. The novel design was accomplished using advanced imaging analysis to improve fit and stability for patients of varying anatomy. The new RSS-S baseplate was designed to achieve immediate fixation with an independent central screw, and the porous-coated central post allows the patient’s bone to grow onto the implant to further maximize the potential for long-term fixation.
“We designed the Titan Reverse Shoulder System-S to leverage the latest data on glenoid morphology in various patient populations, while streamlining the instrumentation to improve the flow of each case,” said Dr. Matthew Ramsey of the Rothman Institute and one of the thought leaders Integra worked with on the design of the system. “The new system builds upon the established legacy of our diaphyseal-fit humeral stems, which allow me to treat my patients without cement in primary and revision surgeries.”
About a month later, Integra announced the launch of the Panta 2 TTC Arthrodesis Nail System for tibio-talo-calcaneal (TTC) fusion of the ankle. TTC fusion is a reconstructive ankle surgery for severe arthritis and complex deformities in which bone-to-bone contact through compression is paramount for long-term success. Panta 2’s new carbon fiber targeting and compression device offers surgeons an unobstructed view intraoperatively of the system’s nail for improved visibility for positioning and identification that bone-to-bone contact has been achieved.
Looking to the potential for future product innovation, Integra also announced it was teaming with a group of orthopedists, Consortium of Focused Orthopedists LLC (CFO), to develop a short stem and stemless shoulder system. According to Integra, the design of the bone-sparing shoulder system will be competitively differentiated, with design features that address limitations of systems currently on the market.
“We designed this system to allow for patients to be anatomically suited to experience the bone-sparing benefits of a short stem,” said Dr. Armodios Hatzidakis, an orthopedic surgeon at Western Orthopaedics, and one of the design surgeons with CFO. “Integra is a proven leader in medical devices with a successful track record of commercializing innovative products that improve patients’ lives. They are a logical choice to partner with to bring this product to market.”